All In Biotech

Free tool

FAERS Monitor: Clarinex-D 12 Hour

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 021313 or its brand name (Clarinex-D 12 Hour, Desloratadine, Pseudoephedrine Sulfate). Reports on generic versions are filed under their own applications.

Reports

39

Serious

23

59% of reports

Hospitalization

6

Death reported

1

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug hypersensitivity4
  • nausea4
  • dizziness3
  • feeling abnormal3
  • insomnia3
  • malaise3
  • product dose omission issue3
  • pruritus3
  • rash3
  • urticaria3
  • abdominal discomfort2
  • anxiety2
  • arthralgia2
  • chest pain2
  • cough2

Reports by year received

View as table
YearReports
20071
20081
20092
20107
20112
20122
20131
20155
20163
20171
20182
20194
20211
20223
20232
20241
20261

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,120 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
drug hypersensitivitySignal411.14.428
urticariaSignal39.73.316
feeling abnormalSignal36.82.310
abdominal discomfort26.41.75
insomniaSignal36.12.08
chest pain25.81.54
product dose omission issueSignal35.51.97
pruritusSignal34.21.45
cough23.81.02
anxiety23.81.02
rash33.71.34
malaise33.71.24
dizziness33.21.13
nausea42.71.13
arthralgia22.60.71

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.